IL311934A - Compositions and methods for enhancing wnt signaling for treating cancer - Google Patents

Compositions and methods for enhancing wnt signaling for treating cancer

Info

Publication number
IL311934A
IL311934A IL311934A IL31193424A IL311934A IL 311934 A IL311934 A IL 311934A IL 311934 A IL311934 A IL 311934A IL 31193424 A IL31193424 A IL 31193424A IL 311934 A IL311934 A IL 311934A
Authority
IL
Israel
Prior art keywords
compositions
methods
cancer treatment
wnt signaling
enhancing wnt
Prior art date
Application number
IL311934A
Other languages
English (en)
Hebrew (he)
Inventor
Jonathan Braverman
George Eng
Omer Yilmaz
Original Assignee
Massachusetts Inst Technology
Massachusetts Gen Hospital
Jonathan Braverman
George Eng
Omer Yilmaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Massachusetts Gen Hospital, Jonathan Braverman, George Eng, Omer Yilmaz filed Critical Massachusetts Inst Technology
Publication of IL311934A publication Critical patent/IL311934A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL311934A 2021-10-07 2022-10-07 Compositions and methods for enhancing wnt signaling for treating cancer IL311934A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163253380P 2021-10-07 2021-10-07
PCT/US2022/077746 WO2023060226A1 (en) 2021-10-07 2022-10-07 Compositions and methods for enhancing wnt signaling for treating cancer

Publications (1)

Publication Number Publication Date
IL311934A true IL311934A (en) 2024-06-01

Family

ID=83978871

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311934A IL311934A (en) 2021-10-07 2022-10-07 Compositions and methods for enhancing wnt signaling for treating cancer

Country Status (8)

Country Link
US (2) US12440497B2 (enExample)
EP (1) EP4412614A1 (enExample)
JP (1) JP2024537192A (enExample)
CN (1) CN118338903A (enExample)
AU (1) AU2022361519A1 (enExample)
CA (1) CA3233974A1 (enExample)
IL (1) IL311934A (enExample)
WO (1) WO2023060226A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106408A1 (en) * 2007-02-27 2008-09-04 Cedars-Sinai Medical Center Treatment of cancer with bio and chemotherapy
JPWO2006073202A1 (ja) * 2005-01-04 2008-08-07 国立大学法人金沢大学 ＧＳＫ３β阻害効果に基づくがんの抑制および抗がん剤の評価方法
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP2016538342A (ja) * 2013-11-18 2016-12-08 イエール ユニバーシティ トランスポゾンを使用する組成物および方法
US20230241000A1 (en) * 2020-06-30 2023-08-03 The Regents Of The University Of California Gsk3 inhibitor-loaded nano formulations as a cancer immunotherapeutic

Also Published As

Publication number Publication date
CA3233974A1 (en) 2023-04-13
US12440497B2 (en) 2025-10-14
CN118338903A (zh) 2024-07-12
US20260091038A1 (en) 2026-04-02
WO2023060226A1 (en) 2023-04-13
JP2024537192A (ja) 2024-10-10
EP4412614A1 (en) 2024-08-14
US20230190767A1 (en) 2023-06-22
AU2022361519A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
IL284199A (en) Csf1r inhibitors for use in treating cancer
SI3986897T1 (sl) Inhibitor EGFR za zdravljenje raka
DK4096717T3 (da) Behandling af cancer
EP4034138A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
EP3850088A4 (en) Compositions and methods for improving base editing
IL282663A (en) Bt1718 for use in treating cancer
EP3668497A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER, INFLAMMATION, OR IMMUNE-REACTION-ASSOCIATED DISEASES
EP3723772A4 (en) COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR THE TREATMENT OF CANCER AND METABOLIC INTERVENTION THERAPY
IL276808A (en) Preparations and methods for the treatment of cancer
MX2020011465A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
EP3983445A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP3589289A4 (en) INHIBITION OF SMARCA2 FOR THE TREATMENT OF CANCER
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
EP3678663A4 (en) POLYTHERAPY FOR CANCER TREATMENT
EP4337329A4 (en) COMBINATIONS FOR CANCER TREATMENT
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
IL290348A (en) Surface treatment compositions and methods
EP3576792A4 (en) METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF CANCER
DK4058474T3 (da) Sammensætninger og fremgangsmåder til behandling af egfr-positive kræftformer
EP3600302A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL287043A (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
IL281600A (en) Methods of treating cancer
IL288086A (en) Methods and materials for treating cancer
IL309662A (en) Compositions and methods for treating cancer
EP4440623A4 (en) Polytherapy for the treatment of cancer